Engineered T Cells for glioblastoma therapy
Engineered T cells therapy holds promise for glioblastoma (GBM) therapy. Genetic modification of T-lymphocytes, using T cell receptors, chimeric antigen receptors, and others, is an attractive antitumor strategy, especially in large solid tumors. Recently, several clinical trials have shown an impre...
Main Authors: | Junjie Zhong, Jianhong Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
Series: | Glioma |
Subjects: | |
Online Access: | http://www.jglioma.com/article.asp?issn=2589-6113;year=2018;volume=1;issue=4;spage=125;epage=131;aulast=Zhong |
Similar Items
-
Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements
by: Edoardo Agosti, et al.
Published: (2023-10-01) -
Prospective approaches to enhancing CAR T cell therapy for glioblastoma
by: Sun Il Choi, et al.
Published: (2022-10-01) -
Advanced Cell Therapies for Glioblastoma
by: Guangwen Wang, et al.
Published: (2022-08-01) -
Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma
by: Shuchang Zhou, et al.
Published: (2023-09-01) -
CAR-NK cell therapy for glioblastoma: what to do next?
by: Qi Xiong, et al.
Published: (2023-06-01)